Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)
Taiwan · Delayed Price · Currency is TWD 151.00
-4.50 (-2.89%)
At close: Oct 8, 2026
TPEX:7871 Revenue
Elixiron Immunotherapeutics (Cayman) Limited had revenue of 63.28M TWD in the half year ending June 30, 2026. This brings the company's revenue in the last twelve months to 113.34M, up 10,946.88% year-over-year. In the year 2025, Elixiron Immunotherapeutics (Cayman) Limited had annual revenue of 50.29M with 6,162.39% growth. That makes Elixiron Immunotherapeutics (Cayman) Limited the 40,951st largest company in the world by revenue and 2,102nd in Taiwan.
Revenue (ttm)
113.34M
Revenue Growth
+10,946.88%
P/S Ratio
178.89
Revenue / Employee
n/a
Employees
n/a
Market Cap
20.28B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 50.29M | 49.48M | 6,162.39% |
| Dec 31, 2024 | 803.00K | -24.89M | -96.88% |
| Dec 31, 2023 | 25.70M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.